Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nkarta, Inc. - Common Stock (NQ:NKTX)

2.135 -0.045 (-2.06%)
Streaming Delayed Price Updated: 9:33 AM EST, Jan 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nkarta, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
NKX101's Leukemia Setting Phase 1 Results a Setback for Nkarta: Analyst Lowers Price Target Amid Revised Development Timeline ↗
Nkarta Inc (NASDAQ: NKTX) announced updated data from the Phase 1 study of NKX101 to treat patients with relapsed or refractory (r/r)  
Via Benzinga
News headline image
Why Walgreens Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) shares jumped 105% to $0.2050 after the company signed a distribution agreement with Cardinal Health. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Analyst Expectations for Nkarta's Future ↗
 
Via Benzinga
News headline image
Nkarta's Updated Data From Leukemia Study Fails To Cheer Investors ↗
Nkarta Inc (NASDAQ: NKTX) announced updated data from the Phase 1 study of NKX101 to treat patients with relapsed or refractory (r/r)  
Via Benzinga
News headline image
Why Shares of Nkarta Are Slumping Tuesday ↗
The pharmaceutical stock dropped after announcing so-so clinical trial results. 
Via The Motley Fool
News headline image
Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program
Call scheduled for Tuesday, June 27, 2023 at 8:00 a.m. ET 
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
News headline image
7 Stocks With Promising Upside Potential for 100% Returns ↗
If you still want to gamble even during this market environment, these are the stocks with 100% upside potential. 
Via InvestorPlace
News headline image
Nkarta Presents Preclinical Data Exploring Gene Knockout Strategies and Combination Agents with NK Cell-Based Therapies at the 2023 AACR Annual Meeting
From Nkarta, Inc.
Via GlobeNewswire
News headline image
3 Biotech Stocks to Watch for Potential Breakthroughs ↗
These biotech stocks have significant upside and realistic breakthrough chances in the current and distant future. 
Via InvestorPlace
News headline image
NVIDIA To Rally Around 19%? Here Are 10 Other Analyst Forecasts For Friday ↗
Wells Fargo raised the price target for Warner Bros. Discovery, Inc. (NASDAQ: WBD) from $13 to $20. Wells Fargo analyst Steven Cahall upgraded the stock from Equal-Weight to Overweight. Warner Bros.... 
Via Benzinga
News headline image
Nkarta Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
News headline image
EXCLUSIVE: Top 10 Searched Tickers On Benzinga Pro In December 2022: Where Do Tesla, Apple, AMC Rank? ↗
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For December 22, 2022 ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  During Thursday's trading, 138 companies set new 52-week lows. 
Via Benzinga
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
Since Robert Hooke discovered cells in 1665 and Theodor Schwann proposed the classical cell theory in 1839, the cell therapy industry has grown by leaps and bounds. 
Via TheNewswire.com
News headline image
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
By Ernest Dela Aglanu, Benzinga 
Via News Direct
News headline image
VF Corp, Verve Therapeutics And Some Other Big Stocks Moving Lower On Monday ↗
U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
News headline image
Why Nkarta Stock (NKTX) Is Volatile During Monday's Session? ↗
Nkarta Inc (NASDAQ: NKTX) shares are trading lower by 5.82% to $8.09, reversing after trading higher during the pre-market session, after the company announced updated data from its Phase 1 dose... 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
The biggest pre-market stock movers for Monday include many Chinese shares that traders will want to keep an eye on today! 
Via InvestorPlace
News headline image
Nkarta Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Nkarta Presents Data Supporting Engineered NK Cell Based Combination Therapies and Next Generation Commercial-Scale Manufacturing Platform at SITC 37th Annual Meeting
From Nkarta, Inc.
Via GlobeNewswire
News headline image
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers ↗
Since Robert Hooke discovered cells in 1665 and Theodor Schwann proposed the classical cell theory in 1839, the cell therapy industry has grown by leaps and bounds. 
Via Benzinga
News headline image
7 Unknown Biotech Stocks That Could Rocket in 2023 ↗
Unknown biotech stocks that are poised for a big rally in 2023. Emerging biotech companies with a promising clinical pipeline. 
Via InvestorPlace
News headline image
Cowen Slashes Price Target On This Stock By Over 78%; Also Check Out Some Other Big PT Changes ↗
Cowen & Co. cut the price target for The RealReal, Inc. (NASDAQ: REAL) from $14 to $3. RealReal shares fell 0.7% to $3.1388 in pre-market trading. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 28, 2022 ↗
  
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.